Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts
| Autor: | N. Yu. Anisimova, V. Y. Kotova, Ilya V. Manukhov, Vadim S. Pokrovsky, Gennadii B. Zavilgelsky, Sergey V. Bazhenov, N. V. Bulushova, D. Zh. Davydov |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Clostridium sporogenes Mice Nude Antineoplastic Agents Apoptosis Pharmacology 03 medical and health sciences chemistry.chemical_compound Mice 0302 clinical medicine In vivo Neoplasms medicine Tumor Cells Cultured Animals Humans Pharmacology (medical) Doxorubicin Cell Proliferation A549 cell Cisplatin Clostridium Mice Inbred BALB C Methionine Antibiotics Antineoplastic biology Drug Synergism biology.organism_classification Xenograft Model Antitumor Assays In vitro Carbon-Sulfur Lyases 030104 developmental biology Oncology chemistry A549 Cells 030220 oncology & carcinogenesis Female Growth inhibition medicine.drug |
| Zdroj: | Investigational new drugs. 37(2) |
| ISSN: | 1573-0646 |
| Popis: | The anti-cancer efficacy of methionine γ-lyase (MGL) from Clostridium sporogenes (C. sporogenes) is described. MGL was active against cancer models in vitro and in vivo. The calculated EC50 values for MGL were 4.4 U/ml for A549, 7.5 U/ml for SK-BR3, 2.4 U/ml for SKOV3, and 0.4 U/ml for MCF7 cells. The combination of doxorubicin (DOX) and MGL was more effective for A549 human lung cancer growth inhibition than either agent alone in vitro and in vivo. MGL reduced the EC50 of doxorubicin from 35.9 μg/mL to 0.01–0.265 μg/mL. The growth inhibitory effect of DOX + MGL on A549 xenografts in vivo was reflective of the results obtained in vitro. The inhibition rate of tumor growth in the combined arm was 57%, significantly higher than that in the doxorubicin (p = 0.033)-alone arm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink